COMMUNIQUÉS West-GlobeNewswire

Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
08/11/2018
CDX-6114 meets safety and tolerability endpoints REDWOOD CITY, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces top-line results from its Phase 1a [...]
Canada House Clinics Partners with Peak Pharma Solutions for Patient Growth
08/11/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Canada House Clinics, the clinic division of Canada House Wellness Group Inc (“Canada House [...]
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018
08/11/2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
08/11/2018
ALPHARETTA, Ga., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update
08/11/2018
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate SAN FRANCISCO, Nov. 08 [...]
ContraFect Announces Third Quarter 2018 Financial Results
08/11/2018
YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update
08/11/2018
ELX-02 has been granted an orphan drug designation by the European Medicines Agency (EMA) for Cystic Fibrosis Advancing several investigational drug candidates from our library in IND enabling studies for rare inherited [...]
Recro Pharma to Participate in Upcoming Investor Conferences
08/11/2018
MALVERN, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today [...]
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring
08/11/2018
– $70.0 Million of Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 – – Company to host conference call and webcast at 8:00am EST – CHESTERBROOK, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Trevena, [...]
Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
08/11/2018
DEVON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]
Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018
08/11/2018
Press Release - No. 22 / 2018 Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018 Copenhagen, November 8, 2018 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 [...]
Virbac : Declaration of the number of shares and voting rights as of October 2018, 31.
08/11/2018
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote au 31 Octobre 2018
08/11/2018
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]
DRAFT DECISIONS OF JSC OLAINFARM EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS SUBMITTED BY INITIATORS - ANNA EMĪLIJA MALIGINA UN NIKA SAVEĻJEVA
08/11/2018
Extraordinary General Meeting of Shareholders of Joint Stock Company Olainfarm, requested by the shareholders Anna Emīlija Maligina and Nika Saveļjeva, will be held on November 22nd, 2018, at 11:00 at the premises of [...]
Interim Report, Third Quarter 2018, BioPorto Group
08/11/2018
November 8, 2018 Announcement no. 18 Highlights FDA clearance of The NGAL Test™ expected by mid-2019 In the beginning of October 2018, the U.S. Food and Drug Administration (“FDA”) requested additional data from [...]
111, Inc. Announces Third Quarter 2018 Unaudited Financial Results
08/11/2018
SHANGHAI, China, Nov. 08, 2018 (GLOBE NEWSWIRE) -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results [...]
Saniona signs option agreement with Initiator Pharma
08/11/2018
PRESS RELEASE November 8, 2018 Saniona, a leading biotech company within ion-channel research, today announced that it has entered into a 1-year option agreement with Initiator Pharma A/S, where Initiator Pharma obtains [...]
The first patient included in PledPharma’s global Phase III program for PledOx®
08/11/2018
STOCKHOLM, November 8, 2018 — PledPharma AB (publ), a Swedish pharmaceutical developer, today announced that the first patient has been enrolled in the company’s global Phase III program with the company’s drug [...]
Financial calendar 2019
08/11/2018
Orphazyme A/S Company announcement No. 13/2018 Company Registration No. 32266355 Copenhagen, November 8, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare [...]

Pages